Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 490 (TSX: $DN.TO) (OTCQX: $VRNDF) (NASDAQ: $GWPH) (NASDAQ: $VFF) (TSX: $VFF.TO)
Today's podcast sponsored by Cannabis Suisse Corp.
(OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in
Switzerland
Delta, Kelowna, BC, November 3, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/110320-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/11031DN-VRNDF-GWPH-VFF.asp
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
Today’s podcast is
sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis
cultivation and distribution company in Switzerland, for recreational tobacco
products and medical CBD oils. The Company's facilities for producing cannabis
are based in Dietikon, Switzerland, and contain the art surveillance equipment
to enable an around the clock webcast. Cannabis Suisse grows high quality,
organic cannabis with sustainable, all-natural principles. The Company's
products are laboratory tested to ensure the end users have access to a
standardized, safe and consistent product. Cannabis Suisse proprietary
trademarked MoldStandard is a quantitative microbiology method for analyzing
yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary
trademarked CannaMec is a method for quantifying and removing residual solvents
during packaging and storage of CBD products. Cannabis Suisse Corp. currently
sells via a distribution network of Swiss retailers and online shops, under the
retail brand Alpine Cannabis.
In
today’s podcast we look at a few public and private company announcements.
Pure
Extracts Technologies Corp., a plant-based extraction company focused
on cannabis, hemp, and functional mushroom sectors, announced that the company’s stock will
commence trading on the Canadian Securities Exchange (“CSE”) under the symbol
“PULL” on November 5, 2020.
“There currently is a tremendous
consumer demand for natural health products with the ability to immediately
enhance our quality of life. With Health Canada officially granting Pure
Extracts a Standard Processing License under the Cannabis Act, this has put us
on a path to deliver full-spectrum oil products by the end of Q4, 2020” said
chief executive officer Ben Nikolaevsky. “Our trading debut on the CSE is
another vote of confidence in our ability to effectively meet the needs of
consumers focused on receiving cannabis, hemp and functional mushroom
products.”
Pure Extracts would like to thank
its expert tradespeople who worked tirelessly on the its state-of-the-art
facility in Pemberton, BC, its team of dedicated employees, and the investors
who have financed the company for a total $9.45MM CAD allowing it to become a
world-class, plant-based extraction company.
Pure Extracts was incorporated under
the BCBCA and has its offices and operations in Pemberton, British Columbia. On
September 25, 2020, Pure Extracts was granted its Standard Processing License
by Health Canada under the Cannabis Act. Pure Extracts is undertaking the operations
of toll processing, white labelling, and developing its own private label of
products incorporating its full spectrum THC and CBD based extracted oils.
Additionally, Pure Extracts is
presently expanding its business to include functional mushrooms extraction by
working on functional mushroom extraction processes compatible with its
existing infrastructure. Pure Extracts has a fully built CO2
extraction facility built to European Union GMP standards and intends to seek
EU GMP certification of its operations allowing it to export its products for
sale in Europe where such products are legal.
DELTA
9 CANNABIS INC. (TSX: DN) (OTCQX: VRNDF) announced that it has now surpassed one
million transactions through its retail cannabis stores since legalization of
recreational cannabis use. The Company opened its first “Delta 9 Cannabis
Store” on October 17, 2018 and has since grown its retail store footprint to
seven operating stores in the Manitoba and Alberta markets.
In addition to achieving the
milestone number of transactions, the Company is pleased to provide the
following statistics in connection with its retail cannabis business;
●
Over 1,000,000 in-store and online
transactions
●
Over $50 Million in-store and online retail
revenues
●
Average transaction size of $50.20 per
transaction
●
Over 1.5 Million unique website visitors to
delta9.ca
●
Over 17,000 square feet of retail store
space averaging $2,021 in revenue per square foot per year.
●
Average Gross Profit margin of
approximately 26%
"We are very pleased with the
revenue growth generated from our retail stores since legalization in
2018," said John Arbuthnot, CEO of Delta 9. “Delta 9 has stayed focused on
its strategy to vertically integrate into the retail segment and leveraging its
retail business as a means to facilitate distribution of Delta 9 branded
products directly to Canadian consumers.”
Management believes that there are a
number of benefits to pursuing a vertical integration strategy into retail
sales including:
●
Control over a direct to consumer sales
force and product distribution;
●
Control over direct to consumer branding
and marketing initiatives;
●
Capturing additional revenues and gross
margin from retail sales; and
●
Direct feedback from consumers regarding
product trends, marketing strategies, etc.
GW
Pharmaceuticals plc (NASDAQ: GWPH), a world leader in the science,
development, and commercialization of cannabinoid prescription medicines, along
with U.S. subsidiary Greenwich Biosciences, today announced that the Company has
initiated the first U.S. Phase 3 clinical trial studying nabiximols for
multiple sclerosis (MS)-associated spasticity.
Nabiximols, known as Sativex®
outside of the U.S. and approved for use to treat MS spasticity in over 25
countries, is a complex botanical medicine formulated from extracts of the
cannabis plant administered as an oral spray. Positive results from three
previous European Phase 3 clinical studies show nabiximols was well-tolerated
and provided continued reductions in patient-reported spasticity for
individuals with MS.
This Phase 3 trial is one of five
pivotal studies planned for nabiximols in MS spasticity, with the remaining
studies on track to commence either later this year or in 2021. GW expects that
a positive result in any one of these five studies will enable an NDA
submission, potentially as early as mid- next year.
“We are excited that the U.S. Phase
3 clinical program evaluating nabiximols in Multiple Sclerosis spasticity is
now recruiting patients, after a delay due to COVID-19. Given the rigorous
studies already conducted on the medicine outside of the U.S., and positive
discussions with the FDA, we believe that we have a clear path to an NDA
submission, potentially as soon as next year, and a significant second product
opportunity for GW in the U.S.,” stated Justin Gover, GW’s Chief Executive
Officer. “Now is the ideal time to develop nabiximols in the U.S. as research
shows a significant percentage of spasticity patients are today self-medicating
using unapproved cannabis products to relieve their spasticity.”
“There is a significant need for new
treatments to address spasticity in MS patients, a challenging condition with
little therapeutic innovation in decades in the United States,” said Dr.
Stephen Krieger, Associate Professor of Neurology at the Mount Sinai Hospital.
“Nabiximols has the potential to be
a rigorously tested and FDA-regulated cannabis-derived medicine for people
living with MS. I look forward to participating as an investigator in this
study which will evaluate the effect of nabiximols on the frequency of muscle
spasms.”
The study is a Phase 3,
double-blind, parallel, placebo-controlled study that will evaluate the safety
and efficacy of nabiximols for spasm frequency over a 12-week period and is
expected to enroll 446 participants. The
first patient is now screened and in baseline evaluation.
Beyond this initial study, the
Company intends to commence the following additional Phase 3 trials of
nabiximols for MS-associated spasticity:
●
Phase 3 muscle tone studies –
placebo-controlled cross-over design
○
N=52; Expected start: Q4 2020 (subject to
COVID)
○
N=190; Expected start: Q1 2021
○
N=36 (nabiximols responders); Expected
start: Q1 2021
●
Phase 3 spasm frequency studies – placebo-controlled
parallel group
○
N=~200 (nabiximols responders); Expected
start: Q2 2021
Village
Farms International, Inc. (NASDAQ: VFF) (TSX: VFF) announced it has completed the acquisition
from Emerald Health Therapeutics, Inc. of 36,958,500 common shares of Pure
Sunfarms Corp. owned by Emerald, representing approximately 41.3% of the issued
and outstanding common shares of Pure Sunfarms. With the completion of the Pure
Sunfarms Transaction, Village Farms now owns 100% of the common shares of Pure
Sunfarms. The acquisition of the Pure Sunfarms shares will be immediately
accretive to Village Farms' net income.
"Village Farms conceived of a
joint venture to launch its Canadian cannabis business, and the result, Pure
Sunfarms, is now one of the leading Canadian cannabis companies. With this
transaction our shareholders will now fully benefit from our initiative,"
said Michael DeGiglio, CEO, Village Farms. "Pure Sunfarms is well
positioned for long-term growth as one of what we believe will be just a small
number of major suppliers to the Canadian cannabis market. Importantly, as part
of the Village Farms organization Pure Sunfarms can now pursue additional
opportunities to further leverage its success to date and increase its earnings
potential. I am pleased to welcome the outstanding management team and
employees of Pure Sunfarms to our organization, and welcome back so many
Village Farms' personnel who transitioned to our cannabis venture in the early
days to ensure that Pure Sunfarms would benefit fully from Village Farms'
decades of experience and site-specific operational expertise. Pure Sunfarms'
CEO, Mandesh Dosanjh, and his entire team have done exceptional work in
bringing Village Farms' vision to reality, and we look forward to their
continued contribution to its success as part of Village Farms going forward."
"The acquisition of the
entirety of Pure Sunfarms is a defining moment for Village Farms, furthering
our transformation to a vertically integrated, plant-based consumer packaged
goods company. It allows us to fully leverage the invaluable cannabis expertise
Village Farms has gained in combination with the organizational strength
underlying the Village Farms produce business to pursue high-growth
opportunities in emerging legal cannabis and CBD markets in the United States
and targeted markets internationally. We will do so with the same
thoughtfulness, prudence, strategic decision making and focus on near-term
profitability and long-term return on invested capital that has been
fundamental to the success of our investment in Pure Sunfarms."
"We especially look forward to
the potential for U.S. regulatory changes that would permit us to pursue our
U.S. cannabis aspirations. With one of the largest greenhouse footprints in the
U.S., located in one of the best regions for growing in the country, alongside
our cannabis success in Canada, we believe there is no company better
positioned for long-term success in the U.S. cannabis industry. We are ready to
move quickly and aggressively as soon as the regulatory environment
permits."
Upon closing of the Pure Sunfarms
Transaction, Pure Sunfarms will be fully consolidated in Village Farms'
financial results. Village Farms will report its third quarter financial
results and the third quarter financial results of Pure Sunfarms on November
13, 2020. Village Farms' financial results for the three and nine months ended
September 30, 2020 will continue to reflect Village Farms' 58.7% ownership of
Pure Sunfarms as an investment in a joint venture.
Once again, today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks
and other ideas on our site using our list of
top stock trading apps including
Robinhood, Acorn, Stash and others.
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock news column, Investor
Ideas Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but
otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. Contact management and IR of each
company directly regarding specific questions. Disclosure: Cannabis Suisse Corp. (OTC: CSUI),is a paid featured company on
Investorideas.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor
Ideas – news, articles, podcasts and stock
directory
